J Korean Ophthalmol Soc > Volume 56(1); 2015 > Article
Journal of the Korean Ophthalmological Society 2015;56(1):62-69.
DOI: https://doi.org/10.3341/jkos.2015.56.1.62    Published online January 15, 2015.
Effect of Primary Intravitreal Bevacizumab Injection on Stage 3 Retinopathy of Prematurity with Plus Signs.
Sung Eun Kim, Tyler Hyung Taek Rim, Christopher Seungkyu Lee
Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea. sklee219@yuhs.ac
Stage 3 플러스 징후를 동반한 미숙아 망막병증에서 일차 유리체강내 베바시주맙 주입술의 효과
김성은⋅임형택⋅이승규
Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea
Abstract
PURPOSE
To evaluate the efficacy and safety of primary intravitreal bevacizumab injection in stage 3 retinopathy of prematurity with plus signs. METHODS: We reviewed retrospectively the medical records of 30 eyes of 16 patients diagnosed with stage 3 retinopathy of prematurity with plus signs treated with primary intravitreal bevacizumab injection between March 1, 2011 and February 28, 2013 and followed up for at least 9 months. RESULTS: Mean gestational age was 26 + 4 weeks +/- 11 days and mean birth weight was 822 +/- 251.4 g. The locations of disease were zone II in 24 eyes and zone III in 6 eyes. Intravitreal bevacizumab injection was performed after the mean 1.3 +/- 1 day after plus signs were detected. Mean postconceptional age at treatment was 38 + 2 weeks +/- 16 days. Mean follow-up period was 16.6 +/- 6.9 months. Plus signs started to regress after the mean 4.6 +/- 2.3 days after injection and completely regressed after the mean 24.3 +/- 12.4 days. Cataract extraction was performed in 1 eye due to a cataract that appeared not associated with the injection procedure, but was regarded as a treatment failure. There were no local or systemic complications. CONCLUSIONS: Primary intravitreal bevacizumab injection in stage 3 retinopathy of prematurity with plus signs demonstrated excellent short-term efficacy and safety.
Key Words: Avastin;Bevacizumab;Retinopathy of prematurity


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2023 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next